ECTRIMS Insights
ECTRIMS 2022 and the Evolution of the Treatment Arena for MS
As our knowledge and understanding of the underlying pathogenesis of MS increases, so the treatment ...read more
Autologous Haematopoietic Stem Cell Transplantation in MS
Autologous haematopoietic stem cell transplantation (AHSCT) was initially approved for the treatment of haematological malignancies. ...read more
The importance of considering quality of life for individuals living with MS
The World Health Organization (WHO) defines Quality of Life (QoL) [1] as an individual’s perception ...read more
